Drug Trial Radar · NCT05460455
A Study to Evaluate Multi-dose of HB0034 in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Jan 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Oct 13, 2022
Primary completion
Jun 9, 2023
Study completion Dec 8, 2023
Sponsor
- Lead sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following multiple-dose.
Conditions
- Healthy
Interventions
Recombinant Humanized Anti-IL-36R Monoclonal antibody and PlaceboDrug
HB0034 and Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with drug related adverse events (AEs)Time frame: up to 2000 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New zealand Clinical Research
Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.